European Regulators Recommend Approval for Roche's Susvimo for nAMD

The European Medicines Agency's CHMP has issued a positive recommendation for Roche's Susvimo, a treatment for neovascular age-related macular degeneration (nAMD). This innovative therapy is designed as the first continuous delivery system for nAMD, using a refillable implant. If approved, it could significantly reduce the frequency of treatments, potentially requiring only two per year, while maintaining vision.